==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb


Details of Th1032 which contains 8 entries.


Entry 1
(1) Primary information
ID1234
ThPP IDTh1032
Therapeutic Peptide/Protein NameCoagulation factor VIIa
SequenceANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQC view full sequnce in fasta
Functional ClassificationIb
Molecular Weight45079.1
Chemical FormulaC1972H3076N560O597S28
Isoelectric Point6.09
Hydrophobicity-0.311
Melting Point (℃)58
Half LifeN.A.
DescriptionRecombinant human coagulation Factor VIIa is intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues, cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Indication/DiseaseFor treatment of hemorrhagic complications in hemophilia A and B.
PharmacodynamicsTo treat bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.
Mechanism of ActionNovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of Distribution121 ± 30 mL/kg [adults]
Clearance33 - 37 mL/h x kg [healthy]
CategoriesCoagulants
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionAutoplex T (anti-inhibitor coagulant complex)
TargetCoagulation factor X,Serine protease hepsin,Tissue factor pathway inhibitor,Vitamin K-dependent gamma-carboxylase,Coagulation factor VII,Tissue factor
Information of corresponding available drug in the market
Brand NameNovoSeven
CompanyNovo Nordisk
Brand DiscriptionNovoSeven is recombinant human coagulation Factor VIIa, intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven (coagulation factor viia recombinant) is a vitamin K-dependent glycoprotein consisting of 4
Prescribed forFor treatment and prevention of bleeding in surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and people with Glanzmann’s thrombasthenia who have a decreased or absent response
Chemical NameN.A.
FormulationEach vial contains approximately 0. 6 mg/mL NovoSeven (coagulation factor viia recombinant) (corresponding to 600 _g/mL). The reconstituted vials have a pH of approximately 5. 5 in sodium chloride (3 mg/mL), calcium chloride dihydrate (1. 5 mg/mL), glycyl
Physcial AppearanceSterile, white lyophilized powder
Route of AdministrationInjection
Recommended DosageFor bleeding episodes, the recommended dose of NovoSeven (coagulation factor viia (recombinant)) for hemophilia A or B patients with inhibitors is 90 _g/kg given every two hours by bolus infusion until hemostasis is achieved, or until thehemostasis has been acheived.
ContraindicationHypersensitivity
Side EffectsRash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; bleeding at the injection site; bloody stools; calf or stomach pain, tenderness, or swelling; chest pain; confusion; dizziness; fainting; numbness.
Useful Linkhttp://www.novosevenrt.com
PubMed ID16418464
3-D StructureTh1032 (View) or (Download)


Entry 2
(2) Primary information
ID1235
ThPP IDTh1032
Therapeutic Peptide/Protein NameCoagulation factor VIIa
SequenceANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQC view full sequnce in fasta
Functional ClassificationIb
Molecular Weight45079.1
Chemical FormulaC1972H3076N560O597S28
Isoelectric Point6.09
Hydrophobicity-0.311
Melting Point (℃)58
Half LifeN.A.
DescriptionRecombinant human coagulation Factor VIIa is intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues, cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Indication/DiseaseFor treatment of hemorrhagic complications in hemophilia A and B.
PharmacodynamicsTo treat bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.
Mechanism of ActionNovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of Distribution153 ± 29 mL/kg [children]
Clearance1375 ± 396 mL/hr [severe hemophilia A male children]
CategoriesThrombotic Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionBebulin VH (factor ix complex)
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful Linkhttp://www.novonordisk.co.in/documents/article_page/document/Haemostasis_FAQ.asp
PubMed ID16418464
3-D StructureTh1032 (View) or (Download)


Entry 3
(3) Primary information
ID1236
ThPP IDTh1032
Therapeutic Peptide/Protein NameCoagulation factor VIIa
SequenceANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQC view full sequnce in fasta
Functional ClassificationIb
Molecular Weight45079.1
Chemical FormulaC1972H3076N560O597S28
Isoelectric Point6.09
Hydrophobicity-0.311
Melting Point (℃)58
Half LifeN.A.
DescriptionRecombinant human coagulation Factor VIIa is intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues, cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Indication/DiseaseFor treatment of hemorrhagic complications in hemophilia A and B.
PharmacodynamicsTo treat bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.
Mechanism of ActionNovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of Distribution280 to 290 mL/kg [congenital Factor VII deficiency]
Clearance57.3 ± 9.5 mL/hr/kg [severe hemophilia A male children]
CategoriesN.A.
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionFebia NF (anti-inhibitor coagulant complex)
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful Linkhttp://www.rxlist.com/novoseven-drug.htm
PubMed ID16418464
3-D StructureTh1032 (View) or (Download)


Entry 4
(4) Primary information
ID1237
ThPP IDTh1032
Therapeutic Peptide/Protein NameCoagulation factor VIIa
SequenceANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQC view full sequnce in fasta
Functional ClassificationIb
Molecular Weight45079.1
Chemical FormulaC1972H3076N560O597S28
Isoelectric Point6.09
Hydrophobicity-0.311
Melting Point (℃)58
Half LifeN.A.
DescriptionRecombinant human coagulation Factor VIIa is intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues, cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Indication/DiseaseFor treatment of hemorrhagic complications in hemophilia A and B.
PharmacodynamicsTo treat bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.
Mechanism of ActionNovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance2767 ± 385 mL/hr [severe hemophilia A men]
CategoriesN.A.
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionFeiba VH (anti-inhibitor coagulant complex)
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful Linkhttp://www.drugs.com/cdi/novoseven.html
PubMed ID16418464
3-D StructureTh1032 (View) or (Download)


Entry 5
(5) Primary information
ID1238
ThPP IDTh1032
Therapeutic Peptide/Protein NameCoagulation factor VIIa
SequenceANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQC view full sequnce in fasta
Functional ClassificationIb
Molecular Weight45079.1
Chemical FormulaC1972H3076N560O597S28
Isoelectric Point6.09
Hydrophobicity-0.311
Melting Point (℃)58
Half LifeN.A.
DescriptionRecombinant human coagulation Factor VIIa is intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues, cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Indication/DiseaseFor treatment of hemorrhagic complications in hemophilia A and B.
PharmacodynamicsTo treat bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.
Mechanism of ActionNovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance37.6 ± 13.1 mL/hr/kg [severe hemophilia A men]
CategoriesN.A.
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionKonyne 80 (factor ix complex)
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful Linkhttp://www.rxlist.com/novoseven-drug/indications-dosage.htm
PubMed ID16418464
3-D StructureTh1032 (View) or (Download)


Entry 6
(6) Primary information
ID1239
ThPP IDTh1032
Therapeutic Peptide/Protein NameCoagulation factor VIIa
SequenceANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQC view full sequnce in fasta
Functional ClassificationIb
Molecular Weight45079.1
Chemical FormulaC1972H3076N560O597S28
Isoelectric Point6.09
Hydrophobicity-0.311
Melting Point (℃)58
Half LifeN.A.
DescriptionRecombinant human coagulation Factor VIIa is intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues, cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Indication/DiseaseFor treatment of hemorrhagic complications in hemophilia A and B.
PharmacodynamicsTo treat bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.
Mechanism of ActionNovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesN.A.
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionProfilnine SD (factor ix complex)
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful LinkN.A.
PubMed ID16418464
3-D StructureTh1032 (View) or (Download)


Entry 7
(7) Primary information
ID1240
ThPP IDTh1032
Therapeutic Peptide/Protein NameCoagulation factor VIIa
SequenceANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQC view full sequnce in fasta
Functional ClassificationIb
Molecular Weight45079.1
Chemical FormulaC1972H3076N560O597S28
Isoelectric Point6.09
Hydrophobicity-0.311
Melting Point (℃)58
Half LifeN.A.
DescriptionRecombinant human coagulation Factor VIIa is intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues, cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Indication/DiseaseFor treatment of hemorrhagic complications in hemophilia A and B.
PharmacodynamicsTo treat bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.
Mechanism of ActionNovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesN.A.
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionProplex T (factor ix complex)
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful LinkN.A.
PubMed ID16418464
3-D StructureTh1032 (View) or (Download)


Entry 8
(8) Primary information
ID1241
ThPP IDTh1032
Therapeutic Peptide/Protein NameCoagulation factor VIIa
SequenceANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQC view full sequnce in fasta
Functional ClassificationIb
Molecular Weight45079.1
Chemical FormulaC1972H3076N560O597S28
Isoelectric Point6.09
Hydrophobicity-0.311
Melting Point (℃)58
Half LifeN.A.
DescriptionRecombinant human coagulation Factor VIIa is intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues, cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Indication/DiseaseFor treatment of hemorrhagic complications in hemophilia A and B.
PharmacodynamicsTo treat bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.
Mechanism of ActionNovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesN.A.
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionBrilinta (ticagrelor)
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful LinkN.A.
PubMed ID16418464
3-D StructureTh1032 (View) or (Download)